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Background: Population pharmacokinetics (PK) of azithromycin (AZ) and chloroquine (CQ) following administration
of fixed-dose combination tablet formulations of AZ and CQ (AZCQ) was evaluated using data from two studies:
1) in children with symptomatic uncomplicated falciparum malaria in sub-Saharan Africa; and 2) in healthy adults in
the United States.
Methods: Study 1 included paediatric subjects randomized to either AZCQ or artemether-lumefantrine treatment in
Cohort 1 (age 5–12 years) and Cohort 2 (age 6–59 months). Dosing of AZCQ was approximately 30 mg/kg AZ and
10 mg/kg CQ once daily for 3 days (for ≥20 kg weight: AZ/CQ 300/100 mg per tablet; 5 to <20 kg weight: AZ/CQ
150/50 mg per tablet). Study 2 included adults randomized to receive either two AZCQ tablets (AZ/CQ 250/155 mg
per tablet) or individual commercial tablets of AZ 500 mg and CQ 300 mg. Serum AZ and plasma CQ concentrations
from both studies were pooled. Population PK models were constructed using standard approaches to evaluate the
concentration-time data for AZ and CQ and to identify any covariates predictive of PK behaviour.
Results: A three-compartment PK model with linear clearance and absorption adequately described AZ data, while a
two-compartment model with linear clearance and absorption and an absorption lag adequately described CQ
data. No overall bias or substantial model misspecification was evident using diagnostic plots and visual predictive
checks. Body weight as an allometric function was the only covariate in the final AZ and CQ PK models. There were
significantly lower AZ (0.488 vs 0.745 [mg•h/L]/[mg/kg], p < 0.00001) and CQ (0.836 vs 1.27 [mg•h/L]/[mg/kg],
p < 0.00001) exposures (AUCinf) normalized by dose (mg/kg) in children compared with the adults.
Conclusions: The PK of AZ and CQ following administration of AZCQ was well described using a three- and two-
compartment model, respectively. AZ and CQ exhibited linear absorption and clearance; the model for CQ included
an absorption lag. Weight was predictive of exposure for both AZ and CQ. Assuming equivalent dosing (mg/kg), AZ
and CQ exposure in children would be expected to be lower than that in adults, suggesting that children may
require a higher dose (mg/kg) than adults to achieve the same AZ and CQ exposure.
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Worldwide, malaria remains a burden to global health.
The World Health Organization reports that approxi-
mately 3.3 billion people were at risk of malaria in 2010,
with the population of sub-Saharan Africa at the highest
risk [1]. The combination of AZ and CQ exhibits
synergistic activity against CQ-resistant strains of
Plasmodium falciparum in vitro and in vivo [2-4].
Results from Phase 2 and 3 studies demonstrated that
the combination of AZ and CQ had ~95% or more
efficacy against symptomatic uncomplicated P. falcip-
arum malaria in various geographic areas [3,5,6]. To be
useful in combination, anti-malarial agents must not
have clinically significant pharmacokinetic (PK) inter-
actions. A lack of a PK interaction between AZ and CQ
has been demonstrated [7]. In healthy adults, CQ did not
have any clinically relevant effect on the PK of AZ; AZ
also did not have any clinically relevant effect on
either the PK of CQ or its active metabolite, desethyl-
chloroquine (DECQ).
For adults, an investigational AZCQ tablet formulation
has been developed containing AZ 250 mg and CQ
155 mg and has been evaluated in a bioavailability study
in healthy adult volunteers with intensive PK sampling
[8]. In this study, the AZCQ tablet was shown to be bio-
equivalent to the AZ 500 mg (Zithromax®, Pfizer Inc,
New York, NY, USA) and CQ 300 mg (Aralen®, Sanofi
Aventis, Bridgewater, NJ, USA) tablets taken individually
in healthy adults using area under the concentration-
time curve (AUC) as the criterion of exposure. Two
additional paediatric AZCQ tablet formulations (AZ
300 mg/CQ 150 mg per tablet and AZ 150 mg/CQ
50 mg per tablet) were developed and evaluated in pae-
diatric patients with malaria in Africa using sparse PK
sampling.
The population PK analysis approach can be helpful
in characterizing drug concentration-time profiles and
between-subject variability in the PK. In addition, these
analyses are useful to identify factors that are predictive
of PK variability. Therefore, this population PK analysis
was performed by combining the data from the bio-
availability and paediatric treatment studies to evaluate
the population PK of AZ and CQ in healthy adults from




PK data from two studies were pooled and analysed. The
first study was an open-label efficacy study that compared
the efficacy of AZCQ versus artemether-lumefantrine
(AL) for the treatment of uncomplicated P. falciparum
malaria in children in sub-Saharan Africa. In this study,
patients were enrolled in two cohorts by age (Cohort 1[5–12 years] and Cohort 2 [6–59 months]) and rando-
mized to either AZCQ or AL treatment. This analysis only
includes data from AZCQ-treated patients. In AZCQ-
treated patients, dosing of AZCQ was based on weight,
with patients receiving approximately 30 mg/kg of AZ
and 10 mg/kg of CQ. AZCQ tablets were given once daily
for three days based on weight (≥20 kg weight: AZ/CQ
300/100 mg strength tablet; 5 to <20 kg weight: AZ/CQ
150/50 mg strength tablet).
The second study was an open-label, randomized, sin-
gle dose study to estimate the bioavailability of AZCQ
tablets in healthy adult volunteers in the US. Subjects
in this study were randomized to receive either two
AZCQ tablets (AZ/CQ 250/155 mg strength tablet; test
treatment) or co-administration of individual commer-
cial tablets of AZ 500 mg and CQ 300 mg (reference
treatment).
Blood sampling and analysis
In the paediatric study, sparse blood samples were col-
lected from both cohorts to determine AZ concentration
in serum and CQ/desethylchloroquine (DECQ) concen-
tration in plasma prior to AZCQ dosing (window: –1 to
0 h) on day 0 and day 2. On day 2, blood samples were
also collected 3 h (window: 2–4 h) and 8 h (window:
6–10 h) after AZCQ dosing. In addition, blood samples
were collected at a random time point on day 7. Blood
samples in the bioavailability study were collected to
assess serum AZ and plasma CQ concentrations at 0
(pre dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and
96 h post dose.
PK samples from both studies were analysed in the
same bioanalytical laboratories (Centero Research in
Houston, TX, USA for CQ and DECQ; Bioanalytical Sys-
tem Ltd in Warwickshire, UK for AZ). Plasma or serum
samples were analysed for serum AZ, plasma CQ and
plasma DECQ concentrations using validated, sensitive,
specific high-performance liquid chromatography with
tandem mass spectrometry assays [8]. The assays had a
lower limit of quantification of 10.0, 1.0 and 0.50 ng/mL
for AZ, CQ and DECQ, respectively. In the data analysis,
observations that were below the limit of quantification
were excluded from the database. The assay accuracy
(expressed as % relative error: %RE) of the quality con-
trol samples used during the sample analysis ranged
from 0% to 6.1% in the paediatric study and from −2.1%
to 4.7% in the adult study for AZ, from −3.2 to 9.8% in
the paediatric study and from −0.4% to 3% in the adult
study for CQ, and from 0.0% to 14.5% in the paediatric
study for DECQ. The assay precision data were ≤ 4.9%
CV in the paediatric study and ≤4.7% in the adult study
for AZ, ≤11.2% CV in the paediatric study and ≤8.9% in
the adult study for CQ, and ≤10.8% in the paediatric
study for DECQ.
Table 1 Covariates assessed in the pharmacokinetic
analysis
Covariate (unit) Type
Actual dose (mg) Continuous




Weight at baseline (kg) Continuous
Height (cm) Continuous
Body surface area at baseline (m2) Continuous
Body mass index at baseline (kg/m2) Continuous
Ideal body weight at baseline (kg) Continuous
Lean body weight at baseline (kg) Continuous
Aspartate aminotransferase at baseline (U/L) Continuous
Alanine aminotransferase at baseline (U/L) Continuous
Bilirubin at baseline (mg/dL) Continuous
Albumin at baseline (g/dL) Continuous
Calculated creatinine clearance at baseline (mL/min) Continuous
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Concentration-time data collected in both studies were ana-
lysed using the mixed-effects modelling tool, NONMEM®
(version 7, level 2; ICON Plc, Dublin, Ireland). All clearance
and distribution parameters are reported as the ratio of
the parameter and bioavailability since oral dosing was
not accompanied by an intravenous dose. All evaluations







CL/F (L/h) 100 (6.1) 31.3 (17
Normalized for weight 0.75 FIXED
V1/F (L) 186 (22.4) 113 (31
Normalized for weight 1 FIXED CL:V1 covarian
Ka (1/h) 0.259 (10.2) NE
Q2/F (L/h) 180 (8.2) NE
Normalized for weight 0.75 FIXED
V2/F (L) 2,890 (4.8) NE
Normalized for weight 1 FIXED
LAG (h) NE NE
Q3/F (L/h) 10.6 (19.0) NE
V3/F (L) 2,610 (46.7) NE
Residual error (%RSE) 0.406 (2.4) NE
%CV, Percent coefficient of variation; %RSE, Relative standard error expressed as pe
variability; Ka, Absorption rate constant; LAG, Lag time; NE, Not estimated; PK, Pharmac
compartment; Q3/F, Inter-compartmental clearance from central to second peripheral
Volume of distribution of first peripheral compartment; V3/F, Volume of distribution ofPopulation PK models were constructed to evaluate the
concentration-time data for AZ and CQ and to identify
any covariates predictive of PK behaviour using standard
approaches. The structural model consisted of a compart-
mental PK model to describe the observed concentration-
time profiles as well as between subject variability in the
PK behaviour. For both AZ and CQ, two- and three-
compartment models were evaluated. In addition, a one-
compartment model was also evaluated for completeness,
but did not describe the data well and was therefore not
used for either drug.
The covariate models in this PK model were defined
to represent the shift in value of the parameter of inter-
est to a value for a hypothetical patient. The reference
patient for this analysis was 40 years of age, weighed
70 kg and had a body surface area of 1.73 m2 and a body
mass index of 15 kg/m2. Covariates examined as poten-
tial predictors of PK activity are listed in Table 1. Only
those covariates that individually influenced the struc-
tural parameters were added to create the full model.
The full model then underwent reduction where covari-
ates were removed one at a time and the impact of
removal was assessed (backward deletion method). The
covariate was retained in the final model if its removal
resulted in an increase in the objective function
of ≥10.83 points (p < 0.001) from the full model.
Two different allometric models using weight norma-
lized PK parameters to size were evaluated [9]. The first
model used an allometric coefficient of 0.75 for clearances
and 1 for volumes. The second model used estimated allo-








.6) 59.1 (2.3) 30.5 (12.2)
0.75 FIXED
.8) 2,870 (4.3) 46.6 (15.7)










rcentage; CL/F, Clearance normalized for bioavailability; IIV, Inter-individual
okinetics; Q2/F, Inter-compartmental clearance from central to first peripheral
compartment; V1/F, Volume of distribution of the central compartment; V2/F,
second peripheral compartment.
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Figure 1 (See legend on next page.)
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Figure 1 Final population pharmacokinetic (PK) model: predicted and observed (A) serum azithromycin (AZ) and (B) plasma
chloroquine (CQ) concentrations versus time after last dose relative to sampling time. Figure 1 shows (A) serum AZ and (B) plasma CQ
measured and predicted concentrations in various age groups. Black filled circles represent observed data points and red open circles are
population predicted values for the final PK model. Good concordance between observed and predicted data points is evident.
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puted using the asymptotic standard errors of the param-
eter estimates.
Results
Subject disposition and demographics
The final dataset consisted of 1,198 and 1,197 evaluable
measurable AZ and CQ concentration observations from
219 subjects including 40 adults, 123 paediatric subjects
aged < 5 years and 56 paediatric subjects aged 5 to 12
years.
Models
The final model for AZ in serum following AZCQ ad-
ministration was a three-compartment model with linear
clearance and absorption and no absorption lag time. The
final model for CQ in plasma was a two-compartment
model with linear clearance and an absorption lag time.
Both models included actual body weight with fixed allo-
metric scaling. In the AZ model, shrinkage was acceptable
(defined as ≤20%) for clearance (CL/F), but was high
(51.8%) for central compartment volume of distribution
(V1/F) that is considered likely due to the sparse sampling
in the paediatric study. In the CQ model, shrinkage was
acceptable for CL/F and V1/F, but was elevated for the ab-
sorption rate constant (62%) that could be due to the
sparse sampling in the paediatric study. The condition
number for the base model was less than 20 (AZ: 13.4;
CQ: 5.3) for both AZ and CQ suggesting no notable co-
linearity. Thus, covariate evaluations on CL/F were con-
sidered appropriate.
DECQ only had sparse concentration data from the
paediatric patients and no data from the adult bioavail-
ability study were available; thus, a population PK model
for DECQ could not be identified.
PK parameters
The parameters for the final AZ and CQ population PK
models are provided in Table 2. Body weight was found
to be influential for both AZ and CQ pharmacokinetics.
Good concordance was noted between the values pre-
dicted from the PK model versus the observed concen-
trations of AZ and CQ (Figure 1). Goodness of fit plots
also indicated that the PK models adequately described
the PK data for both AZ and CQ and did not suggest
substantial bias (Figure 2). A visual predicted check from
all the data in the final model indicated that, for bothAZ and CQ, the majority of observed concentrations fell
within the predicted interquartile ranges (Figure 3).
There was no overall bias or evidence of substantial
model misspecification for either AZ or CQ. Body weight
as an allometric model was the only covariate in the final
AZ and CQ PK models.
The dose-normalized AUC values from time 0 to infi-
nity (AUCinf ) of AZ and CQ were estimated from the re-
spective administered doses and the individual subject
clearances (CL/F) then normalized by the administered
dose divided by body weight (AUCinf/dose = dose/CL/
[dose/weight]). The paediatric population had signifi-
cantly lower values than that of the adult population in
the dose (mg/kg)-normalized AUCinf for both AZ (0.488
vs 0.745 mg*h/L/(mg/kg), p < 0.00001) and CQ (0.836 vs
1.27 mg*h/L/(mg/kg), p < 0.00001), indicating a lower
(L/h/kg) clearance value in adults as compared to paedi-
atric subjects. Comparison of dose-normalized AUCinf
for both AZ and CQ by age group is graphically pre-
sented in Figure 4.Discussion and conclusions
AZ PK and CQ PK were well described using a three-
and two-compartment model, respectively. These models
were in general agreement with models previously pub-
lished [10-13]. In the models of the current study, both
AZ and CQ exhibited linear absorption and clearance in
children and adults, but CQ showed an absorption lag.
Due to the sparse PK sampling in the paediatric study, it
would be difficult to identify such an absorption delay in
the appearance of drug in the paediatric patients, and the
ability to identify if an absorption phase exists because of
the intensive sampling in the adult study. Consequently, it
is not possible to determine if the lag time is the same
in the paediatric patients as in the adults. Previously
published values for AZ PK parameters were generally
consistent with those estimated in the present analysis
[10,12]. For CQ, other studies have found that a two-
compartment model best fit data in women [11] and chil-
dren [13]. However, neither of these models included an
absorption lag or transit.
A positive correlation between age and CQ clearance
was reported by Obua et al. [13], but was not confirmed
in this analysis, although weight and age are highly posi-
tively correlated in paediatric subjects. However, weight
was predictive of exposure for both AZ and CQ in this
analysis.
eniuqorolhC.BnicymorhtizA.A
Figure 2 Goodness of fit plots for all ages for the final (A) serum azithromycin (AZ) and (B) plasma chloroquine (CQ) pharmacokinetic
models. Figure 2 shows goodness of fit plots for (A) serum AZ and (B) plasma CQ measured and predicted concentrations. No systematic bias is
evident and good concordance between observed and predicted concentrations is evident in the aggregate data.
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Figure 3 Visual predictive check for all concentration-time data for (A) serum azithromycin (AZ) and (B) plasma chloroquine (CQ).
Figure 3 shows the log-log plot of the visual predictive check for the final pharmacokinetic model using all data in the dataset. Open blue circles
are observed concentrations. The solid black line represents the median of the predicted data (black dashed lines represent the 95% confidence
interval [CI]). The solid red line represents the median of the actual data (red dashed lines represent the 95% CI). No apparent bias was noted in
the final model and overall performance was considered adequate.
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adults when evaluated on a weight-normalized basis. Allo-
metric models have been developed to address the higher
clearance (L/h/kg) observed in children [14,15]. Assu-
ming equivalent dosing (mg/kg), AZ and CQ expos-
ure in children would be expected to be lower than
that in adults, suggesting that children may require a
higher dose (mg/kg) than adults to achieve the same
AZ and CQ exposure.
In conclusion, pharmacokinetics for AZ and CQ was
well described using a three-compartment model and
two-compartment model, respectively, in both healthy




























Figure 4 Comparison of dose-normalized area under the concentratio
(AZ) and (B) plasma chloroquine (CQ).uncomplicated falciparum malaria following the full
three-day course of AZCQ treatment. Both AZ and CQ
exhibited linear absorption and linear clearance. In ad-
dition, there was an absorption lag in CQ. The effect of
body size on PK was described using an allometric func-
tion based on normalized weight on primary AZ and
CQ PK parameters. Drug clearance (L/h/kg) in children
was higher than that in adults when evaluated on a
weight-normalized basis. This suggests that exposure
(AUC) of AZ and CQ in the paediatric patients would
be expected to be lower than that experienced by the
adults with equal dosing on a mg/kg basis and higher
































n-time curve (AUCinf) by age group for (A) serum azithromycin
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%CV: Percent coefficient of variation; %RSE: Relative standard error expressed
as percentage; AL: Artemether-lumefantrine; AUC: Area under the
concentration-time curve; AUCinf: Area under the concentration-time curve
from time 0 to time infinity; AZ: Azithromycin; AZCQ: Fixed-dose combination
tablet treatment of azithromycin and chloroquine; CL/F: Clearance;
Cmax: Maximum concentration; CQ: Chloroquine; DECQ: Desethylchloroquine;
IIV: Inter-individual variability; Ka: Absorption rate constant; LAG: Lag time;
NE: Not estimated; PK: Pharmacokinetic; Q2/F: Inter-compartmental clearance
from central to first peripheral compartment; Q3/F: Inter-compartmental
clearance from central to second peripheral compartment; Tmax: Time to
maximum concentration; V1/F: Volume of distribution; V2/F: Volume of
distribution of first peripheral compartment; V3/F: Volume of distribution of
second peripheral compartment.
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